Technical Analysis for DVAX - Dynavax Technologies Corporation
| Grade | Last Price | % Change | Price Change |
|---|---|---|---|
| F | 11.21 | 0.36% | 0.04 |
Earnings due: May 8
*** please verify all earnings dates ***| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Down | Down | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Calm After Storm | Range Contraction | 0.00% | |
| Lower Bollinger Band Walk | Weakness | 0.00% | |
| Stochastic Reached Oversold | Weakness | 0.00% | |
| Lower Bollinger Band Touch | Weakness | 0.00% | |
| Oversold Stochastic | Weakness | 0.00% | |
| Down 3 Days in a Row | Weakness | 0.36% | |
| Lower Bollinger Band Touch | Weakness | 0.36% | |
| MACD Bearish Signal Line Cross | Bearish | -1.84% | |
| 20 DMA Resistance | Bearish | -4.68% | |
| MACD Bullish Signal Line Cross | Bullish | -4.68% |
| Alert | Time |
|---|---|
| Lower Bollinger Band Support | about 18 hours ago |
| Fell Below Lower Bollinger Band | about 18 hours ago |
| Fell Below Previous Day's Low | about 18 hours ago |
| Down 1% | about 18 hours ago |
| 60 Minute Opening Range Breakdown | 1 day ago |
Get a Trading Sidekick!
- Earnings date: 05/08/2024
Dynavax Technologies Corporation Description
Dynavax Technologies Corporation, a clinical-stage biopharmaceutical company, discovers and develops novel products to prevent and treat infectious and inflammatory diseases. It develops product candidates based on the use of immunostimulatory sequences and immunoregulatory sequences. Its lead product candidate is HEPLISAV, a Phase III investigational adult hepatitis B vaccine. The company also develops DV1179, a Phase I bifunctional inhibitor of TLR7 and TLR9 for the treatment of autoimmune and inflammatory diseases; and AZD1419, a preclinical drug candidate for the treatment of asthma. It has a strategic alliance with GlaxoSmithKline to discover, develop, and commercialize TLR inhibitors; and a research collaboration and license agreement with AstraZeneca AB for the discovery and development of TLR9 agonist-based therapies for the treatment of asthma and chronic obstructive pulmonary disease. The company was formerly known as Double Helix Corporation and changed its name to Dynavax Technologies Corporation in September 1996. Dynavax Technologies Corporation was founded in 1996 and is based in Berkeley, California.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Inflammatory Diseases Hepatitis B Asthma Chronic Obstructive Pulmonary Disease Pulmonary Disease Autoimmune And Inflammatory Disease Novel Products Tlr7 Tlr9
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 15.15 |
| 52 Week Low | 10.06 |
| Average Volume | 2,018,632 |
| 200-Day Moving Average | 13.51 |
| 50-Day Moving Average | 12.23 |
| 20-Day Moving Average | 11.81 |
| 10-Day Moving Average | 11.52 |
| Average True Range | 0.31 |
| RSI (14) | 33.33 |
| ADX | 20.97 |
| +DI | 18.12 |
| -DI | 31.97 |
| Chandelier Exit (Long, 3 ATRs) | 11.75 |
| Chandelier Exit (Short, 3 ATRs) | 11.95 |
| Upper Bollinger Bands | 12.54 |
| Lower Bollinger Band | 11.08 |
| Percent B (%b) | 0.09 |
| BandWidth | 12.41 |
| MACD Line | -0.27 |
| MACD Signal Line | -0.23 |
| MACD Histogram | -0.0367 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 11.56 | ||||
| Resistance 3 (R3) | 11.53 | 11.40 | 11.50 | ||
| Resistance 2 (R2) | 11.40 | 11.31 | 11.41 | 11.48 | |
| Resistance 1 (R1) | 11.30 | 11.25 | 11.35 | 11.33 | 11.46 |
| Pivot Point | 11.17 | 11.17 | 11.19 | 11.18 | 11.17 |
| Support 1 (S1) | 11.07 | 11.08 | 11.12 | 11.10 | 10.96 |
| Support 2 (S2) | 10.94 | 11.02 | 10.95 | 10.94 | |
| Support 3 (S3) | 10.84 | 10.94 | 10.92 | ||
| Support 4 (S4) | 10.87 |
